Table 1.

Main characteristics of included studies that compared intermediate or therapeutic versus prophylactic dose of thromboprophylaxis in terms of outcomes in hospitalized COVID-19 patients.

Study	Design	N	ICU (%)	Males (%)	I/P or T/P (%)	Type of Anticoagulation
Intermediate versus prophylactic dose
Peperu et al. [30]	R	173	62	56	50/50	LMWH
Sadeghipour et al. [11]	R	562	100	58	49/51	LMWH/UFH
Jimenez-Soto et al. [29]	O	244	0	66	55/45	LMWH
Jonmarker et al. [35]	O	115	100	82	42/58	LMWH
Hsu et al. [34]	O	393	NR	55	4/96	LMWH/UFH/DOAC/VKA
Paolisso et al. [28]	O	450	0	63	20/80	LMWH
Stessel et al. [27]	O	72	100	68	36/64	LMWH
Therapeutic versus prophylactic dose
Lopes et al. [33]	R	615	6	60	51/49	LMWH/DOAC
Lemos et al. [12]	R	20	100	80	50/50	LMWH/UFH
Matli et al. [31]	O	82	0	62	38/62	LMWH/UFH/DOAC/Fondaparinux
Copur et al. [32]	O	115	0	50	40/60	LMWH
Jimenez-Soto et al. [29]	O	186	0	67	41/59	LMWH
Roomi et al. [26]	O	176	NR	NR	19/81	NR
Di Castelnuovo et al. [41]	O	1577	NR	NR	30/70	UFH
Motta et al. [25]	O	374	17	59	20/80	LMWH/UFH
Canoglu et al. [40]	O	154	NR	62	36/64	LMWH
Jonmarker et al. [35]	O	104	100	87	36/64	LMWH
Bolzetta et al. [39]	O	81	0	60	30/70	LMWH/UFH/Fondaparinux
Lynn et al. [38]	O	402	27	54	38/62	LMWH/UFH/DOAC
Ionescu et al. [24]	O	3119	20	49	32/68	LMWH/UFH/DOAC/VKA
Hsu et al. [34]	O	425	NR	55	11/89	LMWH/UFH/DOAC/VKA
Ferguson et al. [37]	O	141	100	55	33/67	LMWH/UFH
Secco et al. [23]	O	112	NR	70	43/57	LMWH/DOAC/VKA/Fondaparinux
Bousquet et al. [36]	O	93	0	NR	34/66	NR

DOAC, direct oral anticoagulants; I, intermediate dose; LMWH, low molecular weight heparin; NR, not reported; O, observational; P, prophylactic dose; R, randomized; T, therapeutic dose; UFH, unfractionated heparin; VKA, vitamin K antagonists.